Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy

Trends in Molecular Medicine

Volumn 22, Issue 5, 2016, Pages 430-445

  Dallmann, Robert ^a,b   Okyar, Alper ^c   Lévi, Francis ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chronotherapy; Chronotoxicity; Circadian clocks; Drug metabolism; Pharmacotherapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; IRINOTECAN; ISONIAZID; LAPATINIB; OXALIPLATIN; PARACETAMOL; PENTOBARBITAL; PETHIDINE; ROSCOVITINE; SUNITINIB; TAMOXIFEN; TOLBUTAMIDE; XENOBIOTIC AGENT; DRUG;

BIOLOGICAL RHYTHM; CELL CYCLE; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; COMPUTER MODEL; DRUG THERAPY; DRUG TOXICITY; ENVIRONMENTAL FACTOR; HUMAN; IN VITRO STUDY; NONHUMAN; ORGANISMS; REGULATORY MECHANISM; REVIEW; TISSUES; XENOBIOTIC METABOLISM; ADVERSE DRUG REACTION; ANIMAL; CHRONOPHARMACOKINETICS; METABOLISM;

ANIMALS; BIOLOGICAL CLOCKS; CHRONOPHARMACOKINETICS; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; DRUG CHRONOTHERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; XENOBIOTICS;

EID: 84962360317     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.03.004     Document Type: Review

References (173)

1. Feillet C., et al. Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:9828-9833.
2. Gaspar L., et al. Human cellular differences in cAMP-CREB signaling correlate with light-dependent melatonin suppression and bipolar disorder. Eur. J. Neurosci. 2014, 40:2206-2215.
3. Gaspar L., Brown S.A. Measuring circadian clock function in human cells. Methods Enzymol. 2015, 552:231-256.
4. Saini C., et al. Real-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks. Genes Dev. 2013, 27:1526-1536.
5. Bieler J., et al. Robust synchronization of coupled circadian and cell cycle oscillators in single mammalian cells. Mol. Syst. Biol. 2014, 10:739.
6. Roche V.P., et al. Thoracic surface temperature rhythms as circadian biomarkers for cancer chronotherapy. Chronobiol. Int. 2014, 31:409-420.
7. Zarrinpar A., et al. Daily eating patterns and their impact on health and disease. Trends Endocrinol. Metab. 2016, 27:69-83.
8. Reinke H., Asher G. Circadian clock control of liver metabolic functions. Gastroenterology 2016, 150:574-580.
9. Feillet C., et al. Coupling between the circadian clock and cell cycle oscillators: implication for healthy cells and malignant growth. Front. Neurol. 2015, 6:96.
10. Dallmann R., et al. Chronopharmacology: new insights and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 2014, 54:339-361.
11. Levi F., Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 2007, 47:593-628.
12. Ortiz-Tudela E., et al. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. Handb. Exp. Pharmacol. 2013, 217:261-288.
13. Jung C.M., et al. Acute effects of bright light exposure on cortisol levels. J. Biol. Rhythms 2010, 25:208-216.
14. Labrecque G., Beauchamp D. Rhythms and pharmacokinetics. Chronotherapeutics 2003, 75-110. Pharmaceutical Press. P.H. Redfern (Ed.).
15. Levi F., Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Exp. Opin. Drug Deliv. 2011, 8:1535-1541.
16. Ahren B., et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013, 36:2543-2550.
17. Kim S.H., et al. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial. Clin. Ther. 2013, 35:1350-1360.
18. Rajput R., et al. Can levothyroxine be taken as evening dose? Comparative evaluation of morning versus evening dose of levothyroxine in treatment of hypothyroidism. J. Thyroid Res. 2011, 2011:505239.
19. Zappe D.H., et al. Time of administration important? Morning versus evening dosing of valsartan. J. Hypertens. 2015, 33:385-392.
20. Li X.M., et al. A circadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res. 2013, 73:7176-7188.
21. Pagani L., et al. Serum factors in older individuals change cellular clock properties. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7218-7223.
22. Azzi A., et al. Circadian behavior is light-reprogrammed by plastic DNA methylation. Nat. Neurosci. 2014, 17:377-382.
23. Lane J.M., et al. Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. Nat. Commun. 2016, 7:10889.
24. Hu Y., et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nat. Commun. 2016, 7:10448.
25. Filipski E., et al. Circadian disruption accelerates liver carcinogenesis in mice. Mutat. Res. 2009, 680:95-105.
26. Evans J.A., Davidson A.J. Health consequences of circadian disruption in humans and animal models. Prog. Mol. Biol. Transl. Sci. 2013, 119:283-323.
27. Martino T.A., et al. Disturbed diurnal rhythm alters gene expression and exacerbates cardiovascular disease with rescue by resynchronization. Hypertension 2007, 49:1104-1113.
28. Marcheva B., et al. Clock genes and metabolic disease. J. Appl. Physiol. 2009, 107:1638-1646.
29. Eckel-Mahan K., Sassone-Corsi P. Metabolism and the circadian clock converge. Physiol. Rev. 2013, 93:107-135.
30. Straif K., et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007, 8:1065-1066.
31. Innominato P.F., et al. The circadian timing system in clinical oncology. Ann. Med. 2014, 46:191-207.
32. Wallach T., Kramer A. Chemical chronobiology: toward drugs manipulating time. FEBS Lett. 2015, 589:1530-1538.
33. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
34. Waring M.J., et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 2015, 14:475-486.
35. Zhang W., et al. Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics 2012, 13:223-231.
36. Siramshetty V.B., et al. WITHDRAWN - a resource for withdrawn and discontinued drugs. Nucleic Acids Res. 2015, 44:D1080-D1086.
37. Greenhalgh J., et al. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal. Pharmacoeconomics 2015, 33:137-148.
38. Wade R., et al. The clinical and cost effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a critique of the evidence. Pharmacoeconomics 2015, 33:457-466.
39. Innominato P.F., et al. Chronotherapy and the molecular clock: clinical implications in oncology. Adv. Drug Deliv. Rev. 2010, 62:979-1001.
40. Ralph M.R., et al. Transplanted suprachiasmatic nucleus determines circadian period. Science 1990, 247:975-978.
41. Mohawk J.A., et al. Central and peripheral circadian clocks in mammals. Annu. Rev. Neurosci. 2012, 35:445-462.
42. Kornmann B., et al. Regulation of circadian gene expression in liver by systemic signals and hepatocyte oscillators. Cold Spring Harb. Symp. Quant. Biol. 2007, 72:319-330.
43. Gerber A., et al. Blood-borne circadian signal stimulates daily oscillations in actin dynamics and SRF activity. Cell 2013, 152:492-503.
44. Mrosovsky N. Locomotor activity and non-photic influences on circadian clocks. Biol. Rev. Camb. Philos. Soc. 1996, 71:343-372.
45. Mistlberger R.E., Skene D.J. Nonphotic entrainment in humans?. J. Biol. Rhythms 2005, 20:339-352.
46. Roenneberg T., et al. The human circadian clock entrains to sun time. Curr. Biol. 2007, 17:R44-R45.
47. Dallmann R., Mrosovsky N. Scheduled wheel access during daytime: a method for studying conflicting zeitgebers. Physiol. Behav. 2006, 88:459-465.
48. Stokkan K-A., et al. Entrainment of the circadian clock in the liver by feeding. Science 2001, 291:490-493.
49. Vollmers C., et al. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21453-21458.
50. Feillet C.A., et al. Lack of food anticipation in Per2 mutant mice. Curr. Biol. 2006, 16:2016-2022.
51. Storch K.F., Weitz C.J. Daily rhythms of food-anticipatory behavioral activity do not require the known circadian clock. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:6808-6813.
52. Chavan R., et al. Liver-derived ketone bodies are necessary for food anticipation. Nat. Commun. 2016, 7:10580.
53. Damiola F., et al. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev. 2000, 14:2950-2951.
54. Barclay J.L., et al. Circadian desynchrony promotes metabolic disruption in a mouse model of shiftwork. PLoS ONE 2012, 7:e37150.
55. Hatori M., et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab. 2012, 15:848-860.
56. Chaix A., et al. Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. Cell Metab. 2014, 20:991-1005.
57. Gill S., Panda S. A Smartphone App reveals erratic diurnal eating patterns in humans that can be modulated for health benefits. Cell Metab. 2015, 22:789-798.
58. Johnson B.P., et al. Hepatocyte circadian clock controls acetaminophen bioactivation through NADPH-cytochrome P450 oxidoreductase. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:18757-18762.
59. DeBruyne J.P., et al. The hepatic circadian clock modulates xenobiotic metabolism in mice. J. Biol. Rhythm 2014, 29:277-287.
60. Matsunaga N., et al. Influence of feeding schedule on 24-h rhythm of hepatotoxicity induced by acetaminophen in mice. J. Pharmacol. Exp. Ther. 2004, 311:594-600.
61. Marcheva B., et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 2010, 466:627-631.
62. Perelis M., et al. Pancreatic β cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. Science 2015, 350:aac4250.
63. Bray M.S., et al. Disruption of the circadian clock within the cardiomyocyte influences myocardial contractile function, metabolism, and gene expression. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1036-H1047.
64. Jeyaraj D., et al. Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature 2012, 483:96-99.
65. Yu X., et al. Circadian factor BMAL1 in histaminergic neurons regulates sleep architecture. Curr. Biol. 2014, 24:2838-2844.
66. Fortier E.E., et al. Circadian variation of the response of T cells to antigen. J. Immunol. 2011, 187:6291-6300.
67. Keller M., et al. A circadian clock in macrophages controls inflammatory immune responses. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21407-21412.
68. Gibbs J., et al. An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. Nat. Med. 2014, 20:919-926.
69. Gibbs J.E., et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:582-587.
70. Cuesta M., et al. Simulated night shift disrupts circadian rhythms of immune functions in humans. J. Immunol. 2016, 196:2466-2475.
71. Li X.M., et al. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res. 2010, 70:3351-3360.
72. Kamdar B.B., et al. Night-shift work and risk of breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2013, 138:291-301.
73. Schernhammer E.S., et al. Rotating night-shift work and lung cancer risk among female nurses in the United States. Am. J. Epidemiol. 2013, 178:1434-1441.
74. Hahm B.J., et al. Bedtime misalignment and progression of breast cancer. Chronobiol. Int. 2013, 31:214-221.
75. 32P content of cancer of the breast. Cancer 1967, 21:193-196.
76. Bjarnason G.A., Jordan R. Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog. Cell Cycle Res. 2000, 4:193-206.
77. Nagoshi E., et al. Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 2004, 119:693-705.
78. Matsuo T., et al. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003, 302:255-259.
79. Levi F., et al. Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 2010, 50:377-421.
80. Kowalska E., et al. NONO couples the circadian clock to the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:1592-1599.
81. Unsal-Kacmaz K., et al. Coupling of human circadian and cell cycles by the timeless protein. Mol. Cell. Biol. 2005, 25:3109-3116.
82. Hirayama J., et al. Common pathways in circadian and cell cycle clocks: light-dependent activation of Fos/AP-1 in zebrafish controls CRY-1a and WEE-1. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10194-10199.
83. Lauriola M., et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat. Commun. 2014, 5:5073.
84. Carroll R., et al. Diurnal variation in probability of death following self-poisoning in Sri Lanka - evidence for chronotoxicity in humans. Int. J. Epidemiol. 2012, 41:1821-1828.
85. Gachon F., et al. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006, 4:25-36.
86. Tomalik-Scharte D., et al. Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam. J. Clin. Pharmacol. 2014, 54:1162-1169.
87. Ballesta A., et al. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput. Biol. 2011, 7:e1002143.
88. Miura N., et al. Mechanisms of cadmium-induced chronotoxicity in mice. J. Toxicol. Sci. 2013, 38:947-957.
89. Li X.M., et al. Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicol. Appl. Pharmacol. 1997, 143:281-290.
90. Hediger M.A., et al. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol. Aspects Med. 2013, 34:95-107.
91. Hamdan A.M., et al. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway. J. Biol. Chem. 2012, 287:17224-17231.
92. Zhang Y.K., et al. Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab. Dispos. 2009, 37:106-115.
93. Okyar A., et al. Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS ONE 2011, 6:e20393.
94. Hayashi Y., et al. Influence of a time-restricted feeding schedule on the daily rhythm of abcb1a gene expression and its function in rat intestine. J. Pharmacol. Exp. Ther. 2010, 335:418-423.
95. Stearns A.T., et al. Diurnal rhythmicity in the transcription of jejunal drug transporters. J. Pharmacol. Sci. 2008, 108:144-148.
96. Kotaka M., et al. Identification of negative transcriptional factor E4BP4-binding site in the mouse circadian-regulated gene Mdr2. Neurosci. Res. 2008, 60:307-313.
97. Iwasaki M., et al. Circadian modulation in the intestinal absorption of P-glycoprotein substrates in monkeys. Mol. Pharmacol. 2015, 88:29-37.
98. Murakami Y., et al. Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology 2008, 135:1636-1644.
99. Okyar A., et al. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance. Chronobiol. Int. 2012, 29:443-453.
100. Oda M., et al. Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice. Mol. Pharmacol. 2014, 85:715-722.
101. Dulong S., et al. Identification of circadian determinants of cancer chronotherapy through in vitro chronopharmacology and mathematical modeling. Mol. Cancer Therap. 2015, 14:2154-2164.
102. Filipski E., et al. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition. Toxicol. Appl. Pharmacol. 2014, 274:471-479.
103. Hughes M.E., et al. Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet. 2012, 8:e1002835.
104. Robles M.S., et al. In-vivo quantitative proteomics reveals a key contribution of post-transcriptional mechanisms to the circadian regulation of liver metabolism. PLoS Genet. 2014, 10:e1004047.
105. Mauvoisin D., et al. Circadian clock-dependent and -independent rhythmic proteomes implement distinct diurnal functions in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:167-172.
106. Zhang R., et al. A circadian gene expression atlas in mammals: implications for biology and medicine. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:16219-16224.
107. Patel V.R., et al. CircadiOmics: integrating circadian genomics, transcriptomics, proteomics and metabolomics. Nat. Methods 2012, 9:772-773.
108. Podobed P., et al. The day/night proteome in the murine heart. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014, 307:R121-R137.
109. Tsimakouridze E.V., et al. Chronomics of pressure overload-induced cardiac hypertrophy in mice reveals altered day/night gene expression and biomarkers of heart disease. Chronobiol. Int. 2012, 29:810-821.
110. Zuber A.M., et al. Molecular clock is involved in predictive circadian adjustment of renal function. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16523-16528.
111. Pembroke W.G., et al. Temporal transcriptomics suggest that twin-peaking genes reset the clock. Elife 2015, 4:e10518.
112. Yang X., et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006, 126:801-810.
113. Ding X., Kaminsky L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43:149-173.
114. Dallmann R., et al. The human circadian metabolome. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2625-2629.
115. Martinez-Lozano Sinues P., et al. Circadian variation of the human metabolome captured by real-time breath analysis. PLoS ONE 2014, 9:e114422.
116. Davies S.K., et al. Effect of sleep deprivation on the human metabolome. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:10761-10766.
117. Giskeodegard G.F., et al. Diurnal rhythms in the human urine metabolome during sleep and total sleep deprivation. Sci. Rep. 2015, 5:14843.
118. Li X., et al. Drug pharmacokinetics determined by real-time analysis of mouse breath. Angew. Chem. Int. Ed. Engl. 2015, 54:7815-7818.
119. Gamez G., et al. Real-time, in vivo monitoring and pharmacokinetics of valproic acid via a novel biomarker in exhaled breath. Chem. Commun. (Camb.) 2011, 47:4884-4886.
120. Abbondante S., et al. Comparative circadian metabolomics reveal differential effects of nutritional challenge in the serum and liver. J. Biol. Chem. 2016, 291:2812-2828.
121. Li X.M., Levi F. Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice. J. Biol. Rhythms 2007, 22:159-166.
122. Ortiz-Tudela E., et al. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int. J. Cancer 2014, 134:2717-2725.
123. Ercolani L., et al. Circadian clock: time for novel anticancer strategies?. Pharmacol. Res. 2015, 100:288-295.
124. Ahowesso C., et al. Sex and dosing-time dependencies in irinotecan-induced circadian disruption. Chronobiol. Int. 2011, 28:458-470.
125. Innominato P.F., et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int. J. Cancer 2012, 131:2684-2692.
126. Tischkau S.A., et al. Circadian clock-controlled regulation of cGMP-protein kinase G in the nocturnal domain. J. Neurosci. 2003, 23:7543-7550.
127. Agostino P.V., et al. Sildenafil accelerates reentrainment of circadian rhythms after advancing light schedules. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9834-9839.
128. An S., et al. A neuropeptide speeds circadian entrainment by reducing intercellular synchrony. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4355-E4361.
129. Liu J., et al. MT and MT melatonin receptors: a therapeutic perspective. Annu. Rev. Pharmacol. Toxicol. 2016, 56:361-383.
130. Zlotos D.P., et al. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J. Med. Chem. 2014, 57:3161-3185.
131. Hirota T., et al. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20746-20751.
132. Barnea M., et al. Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. Biochim. Biophys. Acta 2012, 1822:1796-1806.
133. Meng Q.J., et al. Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15240-15245.
134. Meng Q.J., et al. Ligand modulation of REV-ERBα function resets the peripheral circadian clock in a phasic manner. J. Cell Sci. 2008, 121:3629-3635.
135. Kumar N., et al. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethy l]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol. Pharmacol. 2010, 77:228-236.
136. Chen Z., et al. Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:101-106.
137. Hirota T., et al. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol. 2010, 8:e1000559.
138. Hirota T., et al. Identification of small molecule activators of cryptochrome. Science 2012, 337:1094-1097.
139. Solt L.A., et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 2012, 485:62-68.
140. Lin P., et al. Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice. Biochem. Biophys. Res. Commun. 2015, 460:362-367.
141. Liu J., et al. Chronopharmacokinetics of erlotinib and circadian rhythms of related metabolic enzymes in Lewis tumor-bearing mice. Eur. J. Drug Metab. Pharmacokinet. 2015, Published online July 15, 2015. 10.1007/s13318-015-0284-3.
142. Kloth J.S., et al. Relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence. Clin. Pharmacokinet. 2015, 54:851-858.
143. Szalek E., et al. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits. Eur. Rev. Med. Pharmacol. Sci. 2014, 18:2393-2399.
144. Sallam H., et al. The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model. Chronobiol. Int. 2015, 32:608-614.
145. Okazaki H., et al. Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma. Cancer Res. 2014, 74:543-551.
146. Binkhorst L., et al. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res. Treat. 2015, 152:119-128.
147. Zhang C., et al. Chronopharmacodynamics and chronopharmacokinetics of pethidine in mice. PLoS ONE 2014, 9:e102054.
148. Pekovic-Vaughan V., et al. The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. Genes Dev. 2014, 28:548-560.
149. Miyazaki M., et al. Chronopharmacological assessment identified GLUT4 as a factor responsible for the circadian variation of the hypoglycemic effect of tolbutamide in rats. Drug Metab. Pharmacokinet. 2011, 26:503-515.
150. Souayed N., et al. Circadian-time dependent tolerance and haematological toxicity to isoniazid in murine. Biomed. Pharmacother. 2015, 71:233-239.
151. Kakan X., et al. Clock gene mPer2 functions in diurnal variation of acetaminophen induced hepatotoxicity in mice. Exp. Toxicol. Pathol. 2011, 63:581-585.
152. Li J., et al. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother. Pharmacol. 2015, 76:651-655.
153. Innominato P.F., et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol. Int. 2011, 28:586-600.
154. Giacchetti S., et al. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann. Oncol. 2012, 23:3110-3116.
155. Buttgereit F., Gibofsky A. Delayed-release prednisone - a new approach to an old therapy. Exp. Opin. Pharmacother. 2013, 14:1097-1106.
156. Alten R., et al. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. RMD Open 2015, 1:e000134.
157. Mallappa A., et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 2015, 100:1137-1145.
158. Wang C., et al. Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. J. Clin. Hypertens. 2013, 15:48-54.
159. Liu X., et al. Evening-versus morning-dosing drug therapy for chronic kidney disease patients with hypertension: a systematic review. Kidney Blood Press Res. 2014, 39:427-440.
160. Kozinski M., et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011, 22:579-587.
161. Ando H., et al. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis. Clin. Exp. Pharmacol. Physiol. 2013, 40:227-232.
162. Brunner-Ziegler S., et al. Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects. J. Thromb. Haemost. 2015, 14:316-326.
163. Brown S.A., et al. (Re)inventing the circadian feedback loop. Dev. Cell 2012, 22:477-487.
164. DeBruyne J.P., et al. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat. Neurosci. 2007, 10:543-545.
165. Padmanabhan K., et al. Feedback regulation of transcriptional termination by the mammalian circadian clock PERIOD complex. Science 2012, 337:599-602.
166. Guillaumond F., et al. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J. Biol. Rhythms 2005, 20:391-403.
167. Panda S., et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002, 109:307-320.
168. Lim C., Allada R. Emerging roles for post-transcriptional regulation in circadian clocks. Nat. Neurosci. 2013, 16:1544-1550.
169. Janich P., et al. Ribosome profiling reveals the rhythmic liver translatome and circadian clock regulation by upstream open reading frames. Genome Res. 2015, 25:1848-1859.
170. Jang C., et al. Ribosome profiling reveals an important role for translational control in circadian gene expression. Genome Res. 2015, 25:1836-1847.
171. Reischl S., Kramer A. Kinases and phosphatases in the mammalian circadian clock. FEBS Lett. 2011, 585:1393-1399.
172. +, SIRT1, and the circadian clock. Cold Spring Harb. Symp. Quant. Biol. 2011, 76:31-38.
173. O'Neill J.S., Reddy A.B. Circadian clocks in human red blood cells. Nature 2011, 469:498-503.